Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose bevacizumab in recurrent glioblastoma
IRCT20260924071178N1Phase 2Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in glioblastoma (GBM) and glioma (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Progression-free survival, Overall survival and 3 more. Started Oct 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on IRCT20260924071178N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260924071178N1.